drugset / Trial / NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Completed
23 enrolled
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
Timeline
- Start
- 2011-07
- Primary completion
- 2015-01-21
- Completion
- 2015-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |
Indications
Burkitt lymphoma
MALT lymphoma
Waldenstrom macroglobulinemia
chronic lymphocytic leukemia/small lymphocytic lymphoma
grade III lymphomatoid granulomatosis
intraocular lymphoma
large-cell immunoblastic lymphoma
mantle cell lymphoma
nodal marginal zone B-cell lymphoma
plasma cell myeloma
primary cutaneous B-cell lymphoma
refractory hairy cell leukemia
small intestine lymphoma
splenic marginal zone lymphoma